To address the usefulness of the CD4/CD8 ratio to identify subjects at risk of adverse events, a longitudinal design would be needed, as it appears that our participants might be too young and therefore we do not have any evidence of a higher prevalence of cardiac, metabolic, endocrine, gastrointestinal or psychiatric diseases at this moment. This evidence concerns the gene CD8A and psychiatric disorder.